{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:08:16Z","timestamp":1792782496626,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["T32HL007028"],"award-info":[{"award-number":["T32HL007028"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"name":"French Society of Diabetes"},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["1-18-PDF-174"],"award-info":[{"award-number":["1-18-PDF-174"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IK2BX004659"],"award-info":[{"award-number":["IK2BX004659"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"publisher","award":["McAbee Fellowship"],"award-info":[{"award-number":["McAbee Fellowship"]}],"id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00125-020-05232-2","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T07:03:52Z","timestamp":1596006232000},"page":"2385-2395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Low concentration IL-1\u03b2 promotes islet amyloid formation by increasing hIAPP release from humanised mouse islets in vitro"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6241-9304","authenticated-orcid":false,"given":"Andrew T.","family":"Templin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Mellati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3348-4657","authenticated-orcid":false,"given":"Daniel T.","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1823-3817","authenticated-orcid":false,"given":"Nathalie","family":"Esser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5767-1599","authenticated-orcid":false,"given":"Meghan F.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4080-2545","authenticated-orcid":false,"given":"Joseph J.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6922-350X","authenticated-orcid":false,"given":"Rehana","family":"Akter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3248-7493","authenticated-orcid":false,"given":"Daniel P.","family":"Raleigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4831-7034","authenticated-orcid":false,"given":"Sakeneh","family":"Zraika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9690-4087","authenticated-orcid":false,"given":"Rebecca L.","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7307-9002","authenticated-orcid":false,"given":"Steven E.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"key":"5232_CR1","doi-asserted-by":"publisher","unstructured":"Jurgens CA, Toukatly MN, Fligner CL et al (2011) \u03b2-Cell loss and \u03b2-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol 178(6):2632\u20132640. https:\/\/doi.org\/10.1016\/j.ajpath.2011.02.036","DOI":"10.1016\/j.ajpath.2011.02.036"},{"key":"5232_CR2","doi-asserted-by":"publisher","unstructured":"Zhao H-L, Lai FMM, Tong PCY et al (2003) Prevalence and clinicopathological characteristics of islet amyloid in Chinese patients with type 2 diabetes. Diabetes 52(11):2759\u20132766. https:\/\/doi.org\/10.2337\/diabetes.52.11.2759","DOI":"10.2337\/diabetes.52.11.2759"},{"issue":"2","key":"5232_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1517\/03009734000000014","volume":"77","author":"P Westermark","year":"1972","unstructured":"Westermark P (1972) Quantitative studies on amyloid in the islets of Langerhans. Ups J Med Sci 77(2):91\u201394. https:\/\/doi.org\/10.1517\/03009734000000014","journal-title":"Ups J Med Sci"},{"key":"5232_CR4","doi-asserted-by":"publisher","unstructured":"Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) \u03b2-Cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52(1):102\u2013110. https:\/\/doi.org\/10.2337\/diabetes.52.1.102","DOI":"10.2337\/diabetes.52.1.102"},{"key":"5232_CR5","doi-asserted-by":"publisher","unstructured":"MacArthur DL, de Koning EJ, Verbeek JS, Morris JF, Clark A (1999) Amyloid fibril formation is progressive and correlates with beta-cell secretion in transgenic mouse isolated islets. Diabetologia 42(10):1219\u20131227. https:\/\/doi.org\/10.1007\/s001250051295","DOI":"10.1007\/s001250051295"},{"key":"5232_CR6","doi-asserted-by":"publisher","unstructured":"Kahn SE, D\u2019Alessio DA, Schwartz MW et al (1990) Evidence of cosecretion of islet amyloid polypeptide and insulin by \u03b2-cells. Diabetes 39(5):634\u2013638. https:\/\/doi.org\/10.2337\/diab.39.5.634","DOI":"10.2337\/diab.39.5.634"},{"key":"5232_CR7","doi-asserted-by":"publisher","unstructured":"Westermark P, Wernstedt C, Wilander E, Hayden DW, O\u2019Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci U S A 84(11):3881\u20133885. https:\/\/doi.org\/10.1073\/pnas.84.11.3881","DOI":"10.1073\/pnas.84.11.3881"},{"key":"5232_CR8","doi-asserted-by":"publisher","unstructured":"Westermark P, Wilander E, Westermark GT, Johnson KH (1987) Islet amyloid polypeptide-like immunoreactivity in the islet B cells of type 2 (non-insulin-dependent) diabetic and non-diabetic individuals. Diabetologia 30(11):887\u2013892. https:\/\/doi.org\/10.1007\/BF00274799","DOI":"10.1007\/BF00274799"},{"key":"5232_CR9","doi-asserted-by":"publisher","unstructured":"Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 84(23):8628\u20138632. https:\/\/doi.org\/10.1073\/pnas.84.23.8628","DOI":"10.1073\/pnas.84.23.8628"},{"key":"5232_CR10","doi-asserted-by":"crossref","unstructured":"Westermark P, Engstr\u00f6m U, Johnson KH, Westermark GT, Betsholtz C (1990) Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A 87(13):5036\u20135040","DOI":"10.1073\/pnas.87.13.5036"},{"key":"5232_CR11","doi-asserted-by":"publisher","unstructured":"D\u2019Alessio DA, Verchere CB, Kahn SE et al (1994) Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. Diabetes 43(12):1457\u20131461. https:\/\/doi.org\/10.2337\/diab.43.12.1457","DOI":"10.2337\/diab.43.12.1457"},{"key":"5232_CR12","doi-asserted-by":"publisher","unstructured":"Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC (2004) Diabetes due to a progressive defect in \u03b2-cell mass in rats transgenic for human islet amyloid polypeptide (HIP rat): a new model for type 2 diabetes. Diabetes 53(6):1509\u20131516. https:\/\/doi.org\/10.2337\/diabetes.53.6.1509","DOI":"10.2337\/diabetes.53.6.1509"},{"key":"5232_CR13","doi-asserted-by":"publisher","unstructured":"Soeller WC, Janson J, Hart SE et al (1998) Islet amyloid-associated diabetes in obese A(vy)\/a mice expressing human islet amyloid polypeptide. Diabetes 47(5):743\u2013750. https:\/\/doi.org\/10.2337\/diabetes.47.5.743","DOI":"10.2337\/diabetes.47.5.743"},{"key":"5232_CR14","doi-asserted-by":"publisher","unstructured":"Hiddinga HJ, Sakagashira S, Ishigame M et al (2012) Expression of wild-type and mutant S20G hIAPP in physiologic knock-in mouse models fails to induce islet amyloid formation, but induces mild glucose intolerance. J Diabetes Investig 3(2):138\u2013147. https:\/\/doi.org\/10.1111\/j.2040-1124.2011.00166.x","DOI":"10.1111\/j.2040-1124.2011.00166.x"},{"key":"5232_CR15","doi-asserted-by":"publisher","unstructured":"Meier DT, Entrup L, Templin AT et al (2016) The S20G substitution in hIAPP is more amyloidogenic and cytotoxic than wild-type hIAPP in mouse islets. Diabetologia 59(10):2166\u20132171. https:\/\/doi.org\/10.1007\/s00125-016-4045-x","DOI":"10.1007\/s00125-016-4045-x"},{"key":"5232_CR16","doi-asserted-by":"publisher","unstructured":"Kahn SE, Andrikopoulos S, Verchere CB (1999) Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48(2):241\u2013253. https:\/\/doi.org\/10.2337\/diabetes.48.2.241","DOI":"10.2337\/diabetes.48.2.241"},{"key":"5232_CR17","doi-asserted-by":"publisher","unstructured":"Hull RL, Andrikopoulos S, Verchere CB et al (2003) Increased dietary fat promotes islet amyloid formation and \u03b2-cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes 52(2):372\u2013379. https:\/\/doi.org\/10.2337\/diabetes.52.2.372","DOI":"10.2337\/diabetes.52.2.372"},{"key":"5232_CR18","doi-asserted-by":"publisher","unstructured":"Masters SL, Dunne A, Subramanian SL et al (2010) Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1\u03b2 in type 2 diabetes. Nat Immunol 11(10):897\u2013904. https:\/\/doi.org\/10.1038\/ni.1935","DOI":"10.1038\/ni.1935"},{"key":"5232_CR19","doi-asserted-by":"publisher","unstructured":"Westwell-Roper CY, Ehses JA, Verchere CB (2014) Resident macrophages mediate islet amyloid polypeptide-induced islet IL-1\u03b2 production and \u03b2-cell dysfunction. Diabetes 63(5):1698\u20131711. https:\/\/doi.org\/10.2337\/db13-0863","DOI":"10.2337\/db13-0863"},{"key":"5232_CR20","doi-asserted-by":"publisher","unstructured":"Meier DT, Morcos M, Samarasekera T, Zraika S, Hull RL, Kahn SE (2014) Islet amyloid formation is an important determinant for inducing islet inflammation in high-fat-fed human IAPP transgenic mice. Diabetologia 57(9):1884\u20131888. https:\/\/doi.org\/10.1007\/s00125-014-3304-y","DOI":"10.1007\/s00125-014-3304-y"},{"issue":"5","key":"5232_CR21","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/dom.12873","volume":"19","author":"YJ Park","year":"2017","unstructured":"Park YJ, Warnock GL, Ao Z et al (2017) Dual role of interleukin-1\u03b2 in islet amyloid formation and its \u03b2-cell toxicity: implications for type 2 diabetes and islet transplantation. Diabetes Obes Metab 19(5):682\u2013694. https:\/\/doi.org\/10.1111\/dom.12873","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"5232_CR22","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.molmet.2017.05.016","volume":"6","author":"Q Hui","year":"2017","unstructured":"Hui Q, Asadi A, Park YJ et al (2017) Amyloid formation disrupts the balance between interleukin-1\u03b2 and interleukin-1 receptor antagonist in human islets. Mol Metab 6(8):833\u2013844. https:\/\/doi.org\/10.1016\/j.molmet.2017.05.016","journal-title":"Mol Metab"},{"key":"5232_CR23","doi-asserted-by":"publisher","unstructured":"Westwell-Roper CY, Chehroudi CA, Denroche HC, Courtade JA, Ehses JA, Verchere CB (2015) IL-1 mediates amyloid-associated islet dysfunction and inflammation in human islet amyloid polypeptide transgenic mice. Diabetologia 58(3):575\u2013585. https:\/\/doi.org\/10.1007\/s00125-014-3447-x","DOI":"10.1007\/s00125-014-3447-x"},{"key":"5232_CR24","doi-asserted-by":"publisher","unstructured":"O\u2019Neill CM, Lu C, Corbin KL et al (2013) Circulating levels of IL-1B+IL-6 cause ER stress and dysfunction in islets from prediabetic male mice. Endocrinology 154(9):3077\u20133088. https:\/\/doi.org\/10.1210\/en.2012-2138","DOI":"10.1210\/en.2012-2138"},{"key":"5232_CR25","doi-asserted-by":"publisher","first-page":"2846570","DOI":"10.1155\/2016\/2846570","volume":"2016","author":"CS Nunemaker","year":"2016","unstructured":"Nunemaker CS (2016) Considerations for defining cytokine dose, duration, and milieu that are appropriate for modeling chronic low-grade inflammation in type 2 diabetes. J Diabetes Res 2016:2846570. https:\/\/doi.org\/10.1155\/2016\/2846570","journal-title":"J Diabetes Res"},{"key":"5232_CR26","doi-asserted-by":"publisher","unstructured":"Templin AT, Maier B, Tersey SA, Hatanaka M, Mirmira RG (2014) Maintenance of Pdx1 mRNA translation in islet \u03b2-cells during the unfolded protein response. Mol Endocrinol 28(11):1820\u20131830. https:\/\/doi.org\/10.1210\/me.2014-1157","DOI":"10.1210\/me.2014-1157"},{"key":"5232_CR27","doi-asserted-by":"publisher","unstructured":"Palmer JP, Helqvist S, Spinas GA et al (1989) Interaction of \u03b2-cell activity and IL-1 concentration and exposure time in isolated rat islets of Langerhans. Diabetes 38(10):1211\u20131216. https:\/\/doi.org\/10.2337\/diab.38.10.1211","DOI":"10.2337\/diab.38.10.1211"},{"key":"5232_CR28","doi-asserted-by":"publisher","unstructured":"Jeong I-K, Oh S-H, Chung J-H et al (2002) The stimulatory effect of IL-1\u03b2 on the insulin secretion of rat pancreatic islet is not related with iNOS pathway. Exp Mol Med 34(1):12\u201317. https:\/\/doi.org\/10.1038\/emm.2002.2","DOI":"10.1038\/emm.2002.2"},{"key":"5232_CR29","doi-asserted-by":"publisher","unstructured":"Arous C, Ferreira PG, Dermitzakis ET, Halban PA (2015) Short term exposure of beta cells to low concentrations of interleukin-1\u03b2 improves insulin secretion through focal adhesion and actin remodeling and regulation of gene expression. J Biol Chem 290(10):6653\u20136669. https:\/\/doi.org\/10.1074\/jbc.M114.611111","DOI":"10.1074\/jbc.M114.611111"},{"key":"5232_CR30","doi-asserted-by":"publisher","unstructured":"Hajmrle C, Smith N, Spigelman AF et al (2016) Interleukin-1 signaling contributes to acute islet compensation. JCI Insight 1(4):e86055. https:\/\/doi.org\/10.1172\/jci.insight.86055","DOI":"10.1172\/jci.insight.86055"},{"key":"5232_CR31","doi-asserted-by":"publisher","unstructured":"Zraika S, Hull RL, Udayasankar J et al (2007) Glucose- and time-dependence of islet amyloid formation in vitro. Biochem Biophys Res Commun 354(1):234\u2013239. https:\/\/doi.org\/10.1016\/j.bbrc.2006.12.187","DOI":"10.1016\/j.bbrc.2006.12.187"},{"key":"5232_CR32","doi-asserted-by":"publisher","unstructured":"Bower RL, Yule L, Rees TA et al (2018) Molecular signature for receptor engagement in the metabolic peptide hormone amylin. ACS Pharmacol Transl Sci 1(1):32\u201349. https:\/\/doi.org\/10.1021\/acsptsci.8b00002","DOI":"10.1021\/acsptsci.8b00002"},{"key":"5232_CR33","doi-asserted-by":"publisher","unstructured":"Tu L-H, Serrano AL, Zanni MT, Raleigh DP (2014) Mutational analysis of preamyloid intermediates: the role of his-tyr interactions in islet amyloid formation. Biophys J 106(7):1520\u20131527. https:\/\/doi.org\/10.1016\/j.bpj.2013.12.052","DOI":"10.1016\/j.bpj.2013.12.052"},{"key":"5232_CR34","doi-asserted-by":"publisher","unstructured":"Marek P, Woys AM, Sutton K, Zanni MT, Raleigh DP (2010) Efficient microwave-assisted synthesis of human islet amyloid polypeptide designed to facilitate the specific incorporation of labeled amino acids. Org Lett 12(21):4848\u20134851. https:\/\/doi.org\/10.1021\/ol101981b","DOI":"10.1021\/ol101981b"},{"key":"5232_CR35","doi-asserted-by":"publisher","unstructured":"Abedini A, Raleigh DP (2005) Incorporation of pseudoproline derivatives allows the facile synthesis of human IAPP, a highly amyloidogenic and aggregation-prone polypeptide. Org Lett 7(4):693\u2013696. https:\/\/doi.org\/10.1021\/ol047480+","DOI":"10.1021\/ol047480+"},{"key":"5232_CR36","doi-asserted-by":"publisher","unstructured":"Tu L-H, Raleigh DP (2013) Role of aromatic interactions in amyloid formation by islet amyloid polypeptide. Biochemistry 52(2):333\u2013242. https:\/\/doi.org\/10.1021\/bi3014278","DOI":"10.1021\/bi3014278"},{"key":"5232_CR37","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S0076-6879(99)09020-5","volume":"309","author":"H LeVine","year":"1999","unstructured":"LeVine H (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 309:274\u2013284","journal-title":"Methods Enzymol"},{"key":"5232_CR38","doi-asserted-by":"publisher","unstructured":"Wang F, Hull RL, Vidal J, Cnop M, Kahn SE (2001) Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes 50(11):2514\u20132520. https:\/\/doi.org\/10.2337\/diabetes.50.11.2514","DOI":"10.2337\/diabetes.50.11.2514"},{"key":"5232_CR39","doi-asserted-by":"publisher","unstructured":"Eizirik DL, Flodstr\u00f6m M, Karlsen AE, Welsh N (1996) The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells. Diabetologia 39(8):875\u2013890. https:\/\/doi.org\/10.1007\/BF00403906","DOI":"10.1007\/BF00403906"},{"key":"5232_CR40","doi-asserted-by":"publisher","unstructured":"Donath MY, B\u00f6ni-Schnetzler M, Ellingsgaard H, Halban PA, Ehses JA (2010) Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol Metab 21(5):261\u2013267. https:\/\/doi.org\/10.1016\/j.tem.2009.12.010","DOI":"10.1016\/j.tem.2009.12.010"},{"key":"5232_CR41","doi-asserted-by":"publisher","unstructured":"Stienstra R, Joosten LAB, Koenen T et al (2010) The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 12(6):593\u2013605. https:\/\/doi.org\/10.1016\/j.cmet.2010.11.011","DOI":"10.1016\/j.cmet.2010.11.011"},{"issue":"2","key":"5232_CR42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.2279","volume":"17","author":"B Vandanmagsar","year":"2011","unstructured":"Vandanmagsar B, Youm Y-H, Ravussin A et al (2011 Feb) The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 17(2):179\u2013188. https:\/\/doi.org\/10.1038\/nm.2279","journal-title":"Nat Med"},{"key":"5232_CR43","doi-asserted-by":"publisher","unstructured":"Kahn SE, Verchere CB, Andrikopoulos S et al (1998) Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 47(4):640\u2013645. https:\/\/doi.org\/10.2337\/diabetes.47.4.640","DOI":"10.2337\/diabetes.47.4.640"},{"key":"5232_CR44","doi-asserted-by":"publisher","unstructured":"Hull RL, Shen Z-P, Watts MR et al (2005) Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes 54(7):2235\u20132244. https:\/\/doi.org\/10.2337\/diabetes.54.7.2235","DOI":"10.2337\/diabetes.54.7.2235"},{"key":"5232_CR45","doi-asserted-by":"publisher","unstructured":"Aston-Mourney K, Subramanian SL, Zraika S et al (2013) One year of sitagliptin treatment protects against islet amyloid-associated \u03b2-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice. Am J Physiol Endocrinol Metab 305(4):E475\u2013E484. https:\/\/doi.org\/10.1152\/ajpendo.00025.2013","DOI":"10.1152\/ajpendo.00025.2013"},{"key":"5232_CR46","doi-asserted-by":"publisher","unstructured":"Cardozo AK, Ortis F, Storling J, Feng Y-M, Rasschaert J, Tonnesen M et al (2005) Cytokines downregulate the sarcoendoplasmic reticulum pump Ca2+ ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of endoplasmic reticulum stress in pancreatic \u03b2-cells. Diabetes 54(2):452\u2013461. https:\/\/doi.org\/10.2337\/diabetes.54.2.452","DOI":"10.2337\/diabetes.54.2.452"},{"issue":"4","key":"5232_CR47","first-page":"457","volume":"7","author":"JG Cannon","year":"1988","unstructured":"Cannon JG, van der Meer JW, Kwiatkowski D et al (1988) Interleukin-1\u03b2 in human plasma: optimization of blood collection, plasma extraction, and radioimmunoassay methods. Lymphokine Res 7(4):457\u2013467","journal-title":"Lymphokine Res"},{"key":"5232_CR48","doi-asserted-by":"publisher","unstructured":"Testa M, Yeh M, Lee P et al (1996) Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 28(4):964\u2013971. https:\/\/doi.org\/10.1016\/s0735-1097(96)00268-9","DOI":"10.1016\/s0735-1097(96)00268-9"},{"key":"5232_CR49","doi-asserted-by":"publisher","unstructured":"Badman MK, Pryce RA, Charg\u00e9 SBP, Morris JF, Clark A (1998) Fibrillar islet amyloid polypeptide (amylin) is internalised by macrophages but resists proteolytic degradation. Cell Tissue Res 291(2):285\u2013294. https:\/\/doi.org\/10.1007\/s004410050998","DOI":"10.1007\/s004410050998"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-020-05232-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-020-05232-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-020-05232-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T20:03:44Z","timestamp":1627502624000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-020-05232-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["5232"],"URL":"https:\/\/doi.org\/10.1007\/s00125-020-05232-2","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,29]]},"assertion":[{"value":"1 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}